Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eFT508 (Tomivosertib) in Advanced TNBC and HCC
NCT03318562Phase 2Terminated
- Sponsor
- eFFECTOR Therapeutics
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tomivosertib in triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), sponsored by eFFECTOR Therapeutics. Started Nov 2017; status: terminated.
02
Drugs
tomivosertib
03
Conditions
triple-negative breast cancer (TNBC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03318562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318562.